drugset / Trial / NCT07602335
Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants
Phase 0
Not yet recruiting
24 enrolled
The University of Texas Health Science Center at San Antonio
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
The goal of this clinical trial is to test the safety and to see if there are any side effects of the investigational drug, MCAM. The main aim is to measure blood levels of the study drug after oral administration. Researchers will compare the active study drug to a placebo to test for any differences between the two groups. Participants will be screened for up to 28 days before starting study treatment. Following the screening visit, participants will be admitted to a clinic for 4 days for treatment with either the study drug or placebo. They will attend a follow-up visit on Days 5 and 7 and participate in a follow-up phone call on Day 8. Three different doses will be tested to find the highest safe dose.
Timeline
- Start
- 2026-08-08
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MCAM | Unknown | 3 mg | Oral |
| Subject | MCAM | Unknown | 10 mg | Oral |
| Subject | MCAM | Unknown | 30 mg | Oral |